KalVista Pharmaceuticals reports $13.7 million in net product revenue for third quarter
Reuters
Nov 11
KalVista Pharmaceuticals reports $13.7 million in net product revenue for third quarter
KalVista Pharmaceuticals reported $13.7 million in net product revenue for the third quarter ended September 30, 2025, with cost of revenue at $1.2 million, including manufacturing and inventory overhead costs for EKTERLY after US approval. As of September 30, 2025, the company held approximately $309.2 million in cash, cash equivalents, and marketable securities, which, along with projected revenues from EKTERLY, are expected to fund the company through profitability. The US launch of EKTERLY is showing strong momentum, with 937 patient start forms received through October and increasing repeat prescriptions. EKTERLY was also launched in Germany, with initial orders indicating positive demand, and recently received regulatory approval in Australia. KalVista completed a $144 million convertible note offering during the period.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalvista Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251110740627) on November 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.